It will take years for AI use to peak in drug discovery and development process
Source: Pharmaceutical Technology
Drug discovery and development is a time-consuming, extremely expensive and high-risk process. The research and development (R&D) for a new drug may take 12–18 years with an average cost of $1–3bn. The high attrition rate is one of the biggest challenges associated with the drug discovery and development process—thousands of compounds are subject to early preclinical testing, but only a handful of viable candidates eventually move from clinical trials to commercialisation. Most pharma companies are now focusing on leveraging technologies such as artificial intelligence (AI) to improve the odds of drug discovery and development success.
About GATC
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating novel intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.
Contact Us
Similar News
Lieutenant Colonel (Retired) Wade Jost Joins the Advisory Board of GATC Health Corp
GATC Health, a technology company using advanced multiomic analysis and disruptive artificial intelligence to revolutionize disease detecti…
Read more
Dr. Stanley Lewis Joins the Scientific Advisory Board of GATC Health Corp
GATC Health, an innovative technology company focused on whole genome testing and Predictive Multiomics™, today announced that Dr. Stanley …
Read more
AI-Based Predictions of Molecular Target Activity from Blind Chemical Structures
IRVINE, Calif., June 25, 2024 — GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial int…
Read more